POS-300 Patient-reported early stage chronic kidney disease

Sultan, Alyshah Abdul; Wittbrodt, Eric; Malvolti, Elmas; Guzek, John; Webber, Laura; Retat, Lise; Sánchez, Juan José García; Chen, Hungta; Barone, Salvatore

doi:10.1016/j.ekir.2021.03.316

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advanced CKD (Stages G4-G5) also influences health through other means, affecting elements of functional wellbeing including increased rates of osteoporosis, sarcopenia, and other frailty symptoms [4][5][6]. Progression into later stages of disease (G4-G5) is common and may be related to poor awareness and lack of treatment of CKD in earlier stages [7].…”

Section: Introductionmentioning

confidence: 99%

“…Risk prediction models exist which identify the risk of developing kidney failure over 2 and 5 years in patients with eGFR less than 60 ml/min/m 2 ; however, these models are not effective in earlier stages of CKD and those without but at risk for the disease [12]. This is a problem, as CKD prevalence is significantly higher in these earlier stages, accompanied by lower patient awareness in comparison to those with late-stage CKD [7,13]. Accordingly, given the symptomless nature of earlier CKD stages, diagnosis predominantly occurs much later in disease progression, beginning at stage G3b when symptoms onset [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prediction models for earlier stages of chronic kidney disease

Alexiuk,

Tangri

2024

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Purpose of review Identifying patients with risk of developing progressive chronic kidney disease (CKD) early is an important step in improving kidney care. This review discusses four recently developed models, two which predict risk of new onset disease, and two which predict progression earlier in the course of disease. Recent findings Several models predicting CKD incidence and progression have been recently developed and externally validated. A connecting theme across these models is the use of data beyond estimated glomerular filtration rate, allowing for greater accuracy and personalization. Two models were developed with stratification by diabetes status, displaying excellent model fit with and without variables like use of diabetes medication and hemoglobin A1C. Another model was designed to be patient facing, not requiring the knowledge of any laboratory values for use. The final model was developed using lab data and machine learning. These models demonstrated high levels of discrimination and calibration in external validation, suggesting suitability for clinical use. Summary Models that predict risk of CKD onset and progression have the potential to significantly reduce disease burden, financial cost, and environmental output from CKD through upstream disease prevention and slowed progression. These models should be implemented and evaluated prospectively in primary care settings.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prediction models for earlier stages of chronic kidney disease

Alexiuk,

Tangri

2024

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

show abstract

“…Patients in stages G1 and G2 are often asymptomatic [ 7 ], and studies have shown that up to 93% of patients with evidence of CKD stage G3 are unaware of their clinical status [ 8 ]. This delays access to interventions that could slow down or prevent disease progression.…”

Section: Introductionmentioning

confidence: 99%

Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme

Jha¹,

Al-Ghamdi²,

Li³

et al. 2023

Adv Ther

View full text Add to dashboard Cite

Introduction Chronic kidney disease (CKD) is a progressive disease of growing prevalence, posing serious concerns for global public health. While the economic burden of CKD is substantial, data on the cost of CKD is limited, despite growing pressures on healthcare systems. In this review, we summarise the available evidence in 31 countries and regions and compile a library of costing methodology and estimates of CKD management and disease-associated complications across 31 countries/regions within the Inside CKD programme. Methods We collected country/region-specific CKD costs via a pragmatic rapid literature review of local literature and engagement with local experts. We extracted cost data and definitions from identified sources for CKD stages G3a–5, kidney failure with replacement therapy by modality, covering haemodialysis, peritoneal dialysis, and kidney transplants, and disease-associated complications in local currency, converted to United States dollars (USD) and inflated to 2022. Results Annual direct costs associated with CKD management rose by an average factor of 4 in each country/region upon progression from stage G3a to G5. Mean annual costs per patient increased considerably more from early stages versus dialysis (stage G3a, mean: $3060 versus haemodialysis, mean: $57,334; peritoneal dialysis, mean: $49,490); with estimates for annual costs of transplant also substantially higher (incident: $75,326; subsequent: $16,672). The mean annual per patient costs of complications were $18,294 for myocardial infarction, $8463 for heart failure, $10,168 for stroke and $5975 for acute kidney injury. Costing definitions varied widely in granularity and/or definition across all countries/regions. Conclusion Globally, CKD carries a significant economic burden, which increases substantially with increasing disease severity. We identified significant gaps in published costs and inconsistent costing definitions. Cost-effective interventions that target primary prevention and disease progression are essential to reduce CKD burden. Our results can be used to guide cost collection and facilitate better comparisons across countries/regions to inform healthcare policy. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-023-02608-9.

show abstract

POS-300 Patient-reported early stage chronic kidney disease

Cited by 2 publications

References 0 publications

Prediction models for earlier stages of chronic kidney disease

Prediction models for earlier stages of chronic kidney disease

Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme

Contact Info

Product

Resources

About